Cannabinoid Encyclopedia

Focused research review

How does CBC interact with cannabinoid targets?

What evidence connects CBC with receptor, transporter, target, metabolic, or pharmacology mechanisms?

Updated July 2026 26 research sources Mostly early-stage research

The short answer

What is the bottom line?

Research has examined CBC and cannabinoid targets. This page brings together 4 human-study sources, 10 research reviews, and 11 lab, animal, or mechanism sources. Most of the current evidence is preclinical or focused on biological mechanisms. The studies do not all test the same product, dose, group of people, or outcome, so they cannot be reduced to one answer for every person or product. 1

Choose your next step

Want the quick path or the full picture?

Use this guide the way you need to. Start with the practical question, then open the study detail only when it helps answer something about CBC and cannabinoid targets.

What researchers studiedSee the main areas and the evidence behind each one. Safety and limitsKeep product, dose, medications, and context in view. Open the sourcesGo directly to the studies and references used here.

Key takeaways

What to know first

  1. 1

    Research on CBC and cannabinoid targets covers Receptors, transporters, and pharmacology; those areas should not be combined into one claim. 1

  2. 2

    Most of the current evidence is preclinical or focused on biological mechanisms. 2

  3. 3

    Dose, formulation, route, study population, and outcome can change how closely a study applies to a real-world question. 3

Research areas

What researchers studied about CBC and cannabinoid targets

These are the main questions represented in the current literature. Each link opens a source used to build the overview.

Too limited for a firm answer

Receptors, transporters, and pharmacology

This part of the literature focuses on Receptors, transporters, and pharmacology. Studies may use different compounds, formulations, doses, routes, groups of people, and outcomes, so the details of each source matter. 2

How strong is the research?

Not every study answers the same question

This page separates research in people, research reviews, and earlier-stage biology before interpreting the larger question.

4 sources

Human studies

Research involving people is closest to everyday health questions. The product, dose, population, and outcome still determine what each study can show.

10 sources

Reviews and evidence summaries

Reviews can compare several studies at once. Their conclusion is only as strong and as relevant as the studies they include.

11 sources

Lab, animal, and mechanism research

Early-stage research can explain biological interest. It cannot, by itself, show that the same effect happens in people.

Another 1 of 26 research source could not be placed cleanly into those three groups from the recorded study details.

What these studies actually looked at

The research on CBC and cannabinoid targets is not one kind of study. This source set includes 9 narrative or expert reviews, 7 cell or laboratory studies, 5 animal studies, and 1 systematic review or meta-analysis. 3

The recorded populations or models include people or patients (7 sources), animal models (4 sources), and cells or tissue models (4 sources). A result from one group or model should not be assumed to apply to another. 4

The most common recorded outcome focus is receptor, transporter, target, metabolic, or pharmacology mechanisms (26 sources). Closely related outcome names can still describe different measurements. 5

The CBC and cannabinoid targets source set also contains findings or reviews that remain too limited, indirect, or mixed for a broad answer. That uncertainty is part of the result, not an empty space to fill with assumptions. 6

Examples from the literature

What did the studies actually look at?

Each example names the research question and the study details recorded for that source.

narrative or expert review

Cannabigerol and cannabichromene in Cannabis sativa L.

On this page, this source examines CBC activity involving receptor, transporter, target, metabolic, or pharmacology mechanisms. 1

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
receptor, transporter, target, metabolic, or pharmacology mechanisms
Evidence stage
evidence still limited

narrative or expert review

Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects.

On this page, this source examines CBC activity involving receptor, transporter, target, metabolic, or pharmacology mechanisms. 2

Study type
narrative or expert review
Population or model
people or patients
Outcome focus
receptor, transporter, target, metabolic, or pharmacology mechanisms
Evidence stage
evidence still limited

cell or laboratory study

In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters.

On this page, this source examines CBC activity involving receptor, transporter, target, metabolic, or pharmacology mechanisms. 3

Study type
cell or laboratory study
Population or model
cells or tissue models
Outcome focus
receptor, transporter, target, metabolic, or pharmacology mechanisms
Evidence stage
mechanism-focused research

systematic review or meta-analysis

Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms.

On this page, this source examines CBC activity involving receptor, transporter, target, metabolic, or pharmacology mechanisms. 4

Study type
systematic review or meta-analysis
Outcome focus
receptor, transporter, target, metabolic, or pharmacology mechanisms
Evidence stage
evidence still limited

narrative or expert review

Cannabinoids, inflammation, and fibrosis.

On this page, this source examines CBC activity involving receptor, transporter, target, metabolic, or pharmacology mechanisms. 5

Study type
narrative or expert review
Outcome focus
receptor, transporter, target, metabolic, or pharmacology mechanisms
Evidence stage
evidence still limited

Safety and limits

What should readers keep in mind?

Research on CBC and cannabinoid targets should be read beside safety. A compound can be non-intoxicating or naturally occurring and still have pharmacologic effects, side effects, interactions, or product-quality concerns. 2

Research doses are descriptions of what a study tested. They are not personal dosing instructions. Questions involving medications, pregnancy, children, driving, liver health, heart health, or serious symptoms deserve professional medical guidance.

Drug interactions Pregnancy and children Driving and impairment All safety topics

Common questions

Questions people ask

What evidence connects CBC with receptor, transporter, target, metabolic, or pharmacology mechanisms?

Relevant research is collected here. Most of the current evidence is preclinical or focused on biological mechanisms. 7

Why is there not always a yes-or-no answer?

The sources may test different products, doses, people, and outcomes, so a single conclusion can hide important differences. 8

Where can I read the original studies?

Use the numbered citations and the source list at the bottom of the page to open PubMed or DOI records. 9

Sources

Read the research

The numbered sources below support the main overview. Links open the PubMed record or DOI in a new tab.

  1. 1
    Cannabigerol and cannabichromene in Cannabis sativa L. narrative or expert review; evidence still limited PubMed 36654096 DOI 10.2478/acph-2021-0021
  2. 2
    Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. narrative or expert review; evidence still limited PubMed 21749363 DOI 10.1111/j.1476-5381.2011.01238.x
  3. 3
    In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters. cell or laboratory study; mechanism-focused research PubMed 35306000 DOI 10.1016/j.ejphar.2022.174836
  4. 4
    Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms. systematic review or meta-analysis; evidence still limited PubMed 40967679 DOI 10.1016/bs.pbr.2025.07.006
  5. 5
    Cannabinoids, inflammation, and fibrosis. narrative or expert review; evidence still limited PubMed 27435265 DOI 10.1096/fj.201600646r
  6. 6
    Cannabis: Chemistry, extraction and therapeutic applications. narrative or expert review; evidence still limited PubMed 34838836 DOI 10.1016/j.chemosphere.2021.133012
  7. 7
    Molecular Pharmacology of Phytocannabinoids. narrative or expert review; evidence still limited PubMed 28120231 DOI 10.1007/978-3-319-45541-9_3
  8. 8
    Pharmacokinetics of Non-Psychotropic Phytocannabinoids. narrative or expert review; evidence still limited PubMed 40006604 DOI 10.3390/pharmaceutics17020236
  9. 9
    Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management. narrative or expert review; evidence still limited PubMed 40872492 DOI 10.3390/ph18081101
  10. 10
    The Pharmacology of Cannabinoids in Chronic Pain. narrative or expert review; evidence still limited PubMed 40046175 DOI 10.1159/000543813
  11. 11
    The Potential of Cannabichromene (CBC) as a Therapeutic Agent. narrative or expert review; evidence still limited PubMed 38777605 DOI 10.1124/jpet.124.002166
  12. 12
    Cannabichromene as a Novel Inhibitor of Th2 Cytokine and JAK/STAT Pathway Activation in Atopic Dermatitis Models. animal study; evidence still limited PubMed 39769302 DOI 10.3390/ijms252413539
See all 26 research sources

This complete source list is the deeper research layer for the page. Study type and evidence context are shown when they are available in the current record.

  1. Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. narrative or expert review; evidence still limited / 1 linked research note PubMed 21749363
  2. Anti-Inflammatory Effects of Minor Cannabinoids CBC, THCV, and CBN in Human Macrophages. cell or laboratory study; evidence still limited / 1 linked research note PubMed 37764262
  3. The Potential of Cannabichromene (CBC) as a Therapeutic Agent. narrative or expert review; evidence still limited / 1 linked research note PubMed 38777605
  4. Phytocannabinoids as Novel SGLT2 Modulators for Renal Glucose Reabsorption in Type 2 Diabetes Management. narrative or expert review; evidence still limited / 1 linked research note PubMed 40872492
  5. Pharmacokinetics of Non-Psychotropic Phytocannabinoids. narrative or expert review; evidence still limited / 1 linked research note PubMed 40006604
  6. In vitro evaluation of the interaction of the cannabis constituents cannabichromene and cannabichromenic acid with ABCG2 and ABCB1 transporters. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 35306000
  7. Chemical diversity, receptor binding affinity, and pharmacology of phytocannabinoids: Insights into neuronal mechanisms. systematic review or meta-analysis; evidence still limited / 1 linked research note PubMed 40967679
  8. Molecular Pharmacology of Phytocannabinoids. narrative or expert review; evidence still limited / 1 linked research note PubMed 28120231
  9. Cannabinoids, inflammation, and fibrosis. narrative or expert review; evidence still limited / 1 linked research note PubMed 27435265
  10. Cannabis: Chemistry, extraction and therapeutic applications. narrative or expert review; evidence still limited / 1 linked research note PubMed 34838836
  11. The Pharmacology of Cannabinoids in Chronic Pain. narrative or expert review; evidence still limited / 1 linked research note PubMed 40046175
  12. Effects of cannabidiol, cannabichromene, cannabidivarin, cannabigerol and cannabinol in endometrial cells: Implications for endocrine and senescence modulation. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 40706771
  13. Cannabigerol and cannabichromene in Cannabis sativa L. narrative or expert review; evidence still limited / 1 linked research note PubMed 36654096
  14. Cannabichromene as a Novel Inhibitor of Th2 Cytokine and JAK/STAT Pathway Activation in Atopic Dermatitis Models. animal study; evidence still limited / 1 linked research note PubMed 39769302
  15. Cannabichromene is a cannabinoid CB2 receptor agonist. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 31368508
  16. Effect of Quantitative Structural Properties and Drug Formulation in Four Cannabinoids (Cannabidiol, Cannabigerol, Cannabichromene, and Cannabinol) on Their Lymphatic Transport after Enteral Administration in Rats. animal study; evidence still limited / 1 linked research note PubMed 40611782
  17. Cannabichromene, Related Phytocannabinoids, and 5-Fluoro-cannabichromene Have Anticonvulsant Properties in a Mouse Model of Dravet Syndrome. animal study; evidence still limited / 1 linked research note PubMed 33395525
  18. Cannabichromene: integrative modulation of apoptosis, ferroptosis, and endocannabinoid signaling in pancreatic cancer therapy. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 40790027
  19. Activation of CB2 Receptors by (-)-Cannabichromene but Not (+)-Cannabichromene. cell or laboratory study; mechanism-focused research / 1 linked research note PubMed 39137108
  20. The Oxidation of Phytocannabinoids to Cannabinoquinoids. mechanism-focused research / 1 linked research note PubMed 32315173
  21. Natural Cannabichromene (CBC) Shows Distinct Scalemicity Grades and Enantiomeric Dominance in Cannabis sativa Strains. evidence still limited / 1 linked research note PubMed 37023389
  22. Structure and Dynamics of Cannabinoid Binding to the GABAA Receptor. mechanism-focused research / 1 linked research note PubMed 40271542
  23. The cannabinoid TRPA1 agonist cannabichromene inhibits nitric oxide production in macrophages and ameliorates murine colitis. animal study; mechanism-focused research / 1 linked research note PubMed 23373571
  24. Inhibitory effect of cannabichromene, a major non-psychotropic cannabinoid extracted from Cannabis sativa, on inflammation-induced hypermotility in mice. animal study; mechanism-focused research / 1 linked research note PubMed 22300105
  25. Selected phytocannabinoids inhibit SN-38- and cytokine-evoked increases in epithelial permeability and improve intestinal barrier function in vitro. cell or laboratory study; evidence still limited / 1 linked research note PubMed 38950639
  26. In silico discovery of non-psychoactive scaffolds in Cannabis halting SARS-CoV-2 host entry and replication machinery. mechanism-focused research / 1 linked research note PubMed 35399958